Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The companyâs lead product candidate, AT-001, is a novel aldose reductase inhibitor (ARI) that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Applied Therapeutics is also developing AT-007, a central nervous system penetrant ARI, for the treatment of Galactosemia, a rare pediatric metabolic disease. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy. Source
No articles found.
IMAC Holdings, Inc. owns or manages IMAC Regeneration Centers, which combine life ...
IMAC Holdings, Inc. owns or manages IMAC Regene...
Trevena is a biopharmaceutical company focused on the development and commercializ...
Trevena is a biopharmaceutical company focused ...
Unique and disruptive, PatientDirected.io benefits the patient first. It intends t...
Unique and disruptive, PatientDirected.io benef...
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on th...
G1 Therapeutics, Inc., is a clinical-stage biop...
RB is the global leading consumer health, hygiene and home company. Driven by a pu...
RB is the global leading consumer health, hygie...
Osmotica Pharmaceuticals plc is a fully-integrated biopharmaceutical company focus...
Osmotica Pharmaceuticals plc is a fully-integra...
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel ...
Ultragenyx is a biopharmaceutical company commi...
Join the National Investor Network and get the latest information with your interests in mind.